Stella M F Lima1,2, Mirna S Freire2,3,4, Ana Paula C Cantuária2,5, Danilo C M Martins1,2,5, Ingrid A Amorim2, Elaine M G L Dantas1,2, Jade O Farias1,2, Márcio B Castro6, Jackson S Silva7,8, Fernando A Barriviera8, Maurício Barriviera8, Jeeser A Almeida9, Isadora A Uehara10, Marcelo J B Silva10, Ana Paula L Oliveira11, Osmar N Silva12, Robert E W Hancock13, Octávio L Franco2,3,12, Taia M B Rezende14,15,16. 1. Curso de Odontologia, Universidade Católica de Brasília, Brasília, Distrito Federal, Brazil. 2. Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, SGAN 916N, Av. W5, Campus II, Modulo C, room C-221, Brasília, Distrito Federal, 70790-160, Brazil. 3. Programa de Doutorado da Rede Centro-Oeste, Universidade de Brasília, Brasília, Distrito Federal, Brazil. 4. Curso de Odontologia, Faculdades Integradas da União Educacional do Planalto Central, Brasília, Distrito Federal, Brazil. 5. Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brazil. 6. Laboratório de Patologia Veterinária, Universidade de Brasília, Brasília, Distrito Federal, Brazil. 7. Curso de Odontologia, Centro Universitário do Distrito Federal, Brasília, Distrito Federal, Brazil. 8. Fenelon Radiologia, Brasília, Distrito Federal, Brazil. 9. Programa de Pós Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Universidade Federal de Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil. 10. Laboratório de Biomarcadores Tumorais e Osteoimunologia, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil. 11. Faculdade de Odontologia, Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil. 12. S-Inova Biotech, Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Campo Grande, Mato Grosso do Sul, Brazil. 13. Centre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, British Columbia, Canada. 14. Curso de Odontologia, Universidade Católica de Brasília, Brasília, Distrito Federal, Brazil. taiambr@gmail.com. 15. Centro de Análises Proteômicas e Bioquímicas, Programa de Pós-Graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, SGAN 916N, Av. W5, Campus II, Modulo C, room C-221, Brasília, Distrito Federal, 70790-160, Brazil. taiambr@gmail.com. 16. Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, Distrito Federal, Brazil. taiambr@gmail.com.
Abstract
OBJECTIVES: In order to evaluate host defense peptides (HDPs) HHC-10 and synoeca-MP activity in in vitro osteoclastogenesis process and in vivo induced apical periodontitis, testing the effect of molecules in the inflammatory response and in apical periodontitis size/volume after root canal treatment. MATERIALS AND METHODS: In vitro osteoclastogenesis was assessed on bone marrow cell cultures extracted from mice, while in vivo endodontic treatment involved rats treated with Ca(OH)2 or HDPs. In vitro osteoclasts were subjected to TRAP staining, and in vivo samples were evaluated by radiographic and tomographic exams, as well as histologic analysis. RESULTS: None of the substances downregulated the in vitro osteoclastogenesis. Nevertheless, all treatments affected the average of apical periodontitis size in rats, although only teeth treated with HDPs demonstrated lower levels of the inflammatory process. These results demonstrated the in vivo potential of HDPs. Radiographic analysis suggested that HHC-10 and synoeca-MP-treated animals presented a similar lesion size than Ca(OH)2-treated animals after 7-day of endodontic treatment. However, tomography analysis demonstrated smaller lesion volume in synoeca-MP-treated animals than HHC-10 and Ca(OH)2-treated animals, after 7 days. CONCLUSIONS: These molecules demonstrated an auxiliary effect in endodontic treatment that might be related to its immunomodulatory ability, broad-spectrum antimicrobial activity, and possible induction of tissue repair at low concentrations. These results can encourage further investigations on the specific mechanisms of action in animal models to clarify the commercial applicability of these biomolecules for endodontic treatment. CLINICAL SIGNIFICANCE: HDPs have the potential to be adjuvant substances in endodontic therapy due to its potential to reduce inflammation in apical periodontitis.
OBJECTIVES: In order to evaluate host defense peptides (HDPs) HHC-10 and synoeca-MP activity in in vitro osteoclastogenesis process and in vivo induced apical periodontitis, testing the effect of molecules in the inflammatory response and in apical periodontitis size/volume after root canal treatment. MATERIALS AND METHODS: In vitro osteoclastogenesis was assessed on bone marrow cell cultures extracted from mice, while in vivo endodontic treatment involved rats treated with Ca(OH)2 or HDPs. In vitro osteoclasts were subjected to TRAP staining, and in vivo samples were evaluated by radiographic and tomographic exams, as well as histologic analysis. RESULTS: None of the substances downregulated the in vitro osteoclastogenesis. Nevertheless, all treatments affected the average of apical periodontitis size in rats, although only teeth treated with HDPs demonstrated lower levels of the inflammatory process. These results demonstrated the in vivo potential of HDPs. Radiographic analysis suggested that HHC-10 and synoeca-MP-treated animals presented a similar lesion size than Ca(OH)2-treated animals after 7-day of endodontic treatment. However, tomography analysis demonstrated smaller lesion volume in synoeca-MP-treated animals than HHC-10 and Ca(OH)2-treated animals, after 7 days. CONCLUSIONS: These molecules demonstrated an auxiliary effect in endodontic treatment that might be related to its immunomodulatory ability, broad-spectrum antimicrobial activity, and possible induction of tissue repair at low concentrations. These results can encourage further investigations on the specific mechanisms of action in animal models to clarify the commercial applicability of these biomolecules for endodontic treatment. CLINICAL SIGNIFICANCE: HDPs have the potential to be adjuvant substances in endodontic therapy due to its potential to reduce inflammation in apical periodontitis.
Authors: J J Segura-Egea; K Gould; B Hakan Şen; P Jonasson; E Cotti; A Mazzoni; H Sunay; L Tjäderhane; P M H Dummer Journal: Int Endod J Date: 2017-06-14 Impact factor: 5.264
Authors: Athina Christina Georgiou; Wim Crielaard; Iakovos Armenis; Ralph de Vries; Suzette V van der Waal Journal: J Endod Date: 2019-09-19 Impact factor: 4.171
Authors: N J Kassebaum; A G C Smith; E Bernabé; T D Fleming; A E Reynolds; T Vos; C J L Murray; W Marcenes Journal: J Dent Res Date: 2017-04 Impact factor: 6.116